ArticleAIDS and behavior2026
Integrating Housing and HIV Care: Evaluation of the Implementation and Impact of Three Differentiated Service Delivery Housing Pilots in New York City.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The HIV/AIDS Services Administration (HASA) provides housing, benefits, and case management for low-income people with HIV (PWH) in New York City (NYC). HASA implemented three differentiated service delivery (DSD) pilots: Permanent Supportive Housing (PSH), Transitional Supportive Housing (TSH), and Emergency Single Room Occupancy (ESRO), testing tiered case management by housing type. The PSH pilot aimed to maintain viral suppression outcomes with higher caseloads (50:1), while the TSH and ESRO pilots aimed to improve outcomes with lower caseloads (25:1). We merged programmatic data with the NYC HIV Surveillance Registry to compare 6-month viral load suppression (VLS) and 12-month durable viral suppression (DVS) between pilot and non-pilot clients with follow-up through August 2022. Adjusted risk ratios (aRR) were estimated using log-binomial models. Actual caseload ratios were lower than planned: PSH (36:1), TSH (17:1), and ESRO (24:1, near its 25:1 target) compared with ~ 34:1 in non-pilot arms. VLS rates were higher among pilot clients: PSH (77% vs. 72%; aRR 1.03, 95% CI 0.99-1.07), TSH (65% vs. 56%; 1.06, 1.01-1.11), and ESRO (50% vs. 46%; 1.08, 0.99-1.17). DVS showed similar trends: PSH (70% vs. 62%; 1.05, 0.98-1.11), TSH (51% vs. 41%; 1.13, 1.05-1.22), and ESRO (37% vs. 29%; 1.11, 0.88-1.39). Implemented partly during the COVID-19 pandemic, the PSH and TSH pilots met their goals of maintaining or improving VLS and DVS, though lower-than-planned caseload ratios may have influenced outcomes. The ESRO pilot may have improved VLS slightly, but wide confidence intervals due to under-enrollment limit interpretation of DVS effects.
Indexed as
Identifiers
42828718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.